Faeth Therapeutics to Participate in Upcoming September Investor Conferences

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics(Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that management will participate in the following upcoming investor conferences:

• Wells Fargo 21st Annual Healthcare ConferenceTuesday, September 8, 20261x1 investor meetingsBoston, MA

• Citi Biopharma Back to School SummitWednesday, September 9, 2026Fireside chat at 10:00 a.m. ETNew York, NY

• Cantor Global Healthcare Conference 2026Thursday, September 10, 2026Fireside chat at 8:35 a.m. ETNew York, NYWebcast Link

• Morgan Stanley 24th Annual Global Healthcare ConferenceMonday, September 14 & Wednesday, September 16, 2026Fireside chat at 9:15 a.m. EDT on WednesdayNew York, NYWebcast Link

• Baird Global Healthcare ConferenceTuesday, September 15, 2026Fireside chat at 10:15 a.m. ETNew York, NY

• H.C. Wainwright 28th Annual Global Investment ConferenceWednesday, September 16, 2026Fireside chat at 10:30 a.m. ETNew York, NY

• Deutsche Bank 2026 Healthcare SummitThursday, September 17, 20261x1 investor meetingsNew York, NY

Live webcasts of the Cantor and Morgan Stanley fireside chats can be accessed via the Events and Presentations section of the Faeth website atinvestors.faeththerapeutics.com. Replays will be available for approximately 90 days following the event.

Faeth Therapeutics, Inc. (Nasdaq: FTH) is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The Company’s lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. Faeth was co-founded in 2019 by Anand Parikh and Oliver Maddocks, Ph.D., together with scientific founders Lewis Cantley, Ph.D., the discoverer of the PI3K pathway; Siddhartha Mukherjee, M.D., D.Phil.; Karen Vousden, Ph.D.; Scott Lowe, Ph.D.; and Greg Hannon, Ph.D. For more information, please visitwww.faeththerapeutics.comand follow the Company onLinkedIn.